Why This Landed on My Radar
If you’ve been watching private equity roll up practices in your market and thinking “how are they doing this in states with corporate practice of medicine restrictions?” - regulators are asking the same question. A new comprehensive report from the Private Equity Stakeholder Project shows that six states have already enacted laws specifically targeting the MSO structures, sale-leasebacks, and debt arrangements that PE firms use to gain control without technically owning practices. This isn’t theoretical anymore - the regulatory ground is shifting under a business model that’s reshaped our competitive landscape.
Here’s What’s Going On
The Private Equity Stakeholder Project just released their 2026 State Healthcare Policy Review, tracking how states are moving beyond simple pre-merger notifications to scrutinize the actual mechanisms of private equity control in healthcare. As of August 2026, six states have enacted nine distinct healthcare oversight laws - Washington, Vermont, Delaware, Illinois, Maine, and Connecticut all passed legislation in the last year, while California and Oregon are implementing even more comprehensive frameworks passed in 2025.
What makes this different from previous regulatory efforts is how granular it gets. These laws aren’t just looking at hospital mergers or direct physician practice acquisitions. They’re specifically targeting the structures PE firms have used to work around corporate practice of medicine laws: management services organizations (MSOs) that control everything except the clinical license, sale-leaseback arrangements that create landlord leverage, and debt structures that give investors effective control through financial covenants. The report documents 1,029 private equity-backed healthcare entities across both acute and ambulatory settings - a footprint large enough that state regulators are treating this as a systemic concern, not isolated transactions.
The legislative language in these new laws shows regulators have done their homework. They’re requiring disclosure of “material change transactions” that includes MSO agreements, real estate deals that affect operational control, and debt arrangements that give lenders governance rights. Some states are adding review periods of 90-120 days and setting standards around maintaining access to care and preserving existing payer contracts - essentially creating regulatory friction that makes the PE playbook more expensive and uncertain.
What This Means for Your Practice
For those of us staying independent in Texas, this creates a complex new dynamic. On one hand, Texas hasn’t joined this regulatory wave yet - our state has historically taken a lighter touch on healthcare market structure, and without Medicaid expansion or certificate-of-need laws, we’ve been more of a free-market environment. But that doesn’t mean this won’t affect us.
First, the national regulatory trend changes the calculus for PE-backed groups operating here. If they’re facing tighter scrutiny in California, Oregon, and Illinois, Texas becomes relatively more attractive for aggressive expansion. We could see accelerated consolidation in our major metros - Houston, Dallas, Austin, San Antonio - as PE groups focus capital where regulatory barriers are lower. That means more competition for staff (they can outbid us), more aggressive payer contracting (they have scale leverage with BCBS Texas and United), and more pressure on real estate costs as they buy up medical office buildings.
Second, if you’ve been approached about selling to a PE-backed group or joining an MSO structure, understand that the model itself is under regulatory scrutiny nationally. The physicians I know who signed MSO deals in 2023-2024 thinking it was a safe middle ground between full sale and independence are now watching carefully. If Texas eventually follows other states with similar oversight - and the TMA has been tracking these issues closely - those arrangements could face retroactive review or disclosure requirements.
Third, this matters for payer strategy. The large PE-backed multi-specialty groups are capturing significant Medicare Advantage lives through aggressive HCC coding and care management infrastructure we can’t match alone. With V28 changes making accurate risk adjustment even more valuable, they have the resources to invest in coding audits, AI-powered chart review, and dedicated HCC capture programs. If regulatory friction slows their expansion or forces divestitures in other states, that could actually create opportunities - Medicare Advantage plans will need high-performing independent practices to fill network gaps.
The real strategic question is whether staying independent means staying isolated. The practices I see thriving aren’t trying to match PE groups dollar-for-dollar on overhead, but they are finding ways to get scale benefits through clinically integrated networks, shared technology infrastructure, and collaborative payer contracting. Because ultimately, whether regulators slow PE consolidation or not, the underlying pressures remain: thin margins, workforce shortages, rising patient expectations around access and technology, and payers who increasingly want to contract with groups that can manage population health risk.
Key Takeaways
- Six states have enacted specific laws targeting MSO structures, sale-leasebacks, and debt arrangements used by private equity - the regulatory environment is tightening nationally, even if Texas hasn’t moved yet
- PE-backed groups may accelerate Texas expansion as other states add regulatory friction, intensifying local competition for staff, real estate, and payer contracts
- If you’re considering an MSO arrangement or partial sale, understand the model itself is under scrutiny - what looks like a safe middle ground today could face regulatory challenges tomorrow
- The scale advantages PE groups have in HCC capture, MA contracting, and care management infrastructure are real - staying independent doesn’t mean staying isolated; look for collaboration models that provide scale benefits
- TMA is tracking these developments closely - stay engaged with your county medical society to understand if Texas legislative action is coming
What Smart Practices Are Doing
The independent practices navigating this best aren’t ignoring the competitive pressure from PE consolidation, but they’re also not panic-selling. They’re joining clinically integrated networks that give them negotiating leverage with BCBS Texas and United without giving up ownership, investing selectively in technology that improves revenue cycle and care management performance, and building referral relationships with the employed and PE-backed physicians who are now their neighbors. They’re treating independence as a strategic choice that requires active management, not a passive default.
Source
2026 State Healthcare Policy Review: Tracking Private Equity Oversight and Reform, Private Equity Stakeholder Project via HIT Consultant
Primary Care Perspective delivers curated intelligence from trusted healthcare sources.
© 2026 Primary Care Perspective | Texas Edition